Elevated progranulin contributes to synaptic and learning deficit due to loss of fragile X mental retardation protein

Brain. 2017 Dec 1;140(12):3215-3232. doi: 10.1093/brain/awx265.

Abstract

Fragile X syndrome is an inheritable form of intellectual disability caused by loss of fragile X mental retardation protein (FMRP, encoded by the FMR1 gene). Absence of FMRP caused overexpression of progranulin (PGRN, encoded by GRN), a putative tumour necrosis factor receptor ligand. In the present study, we found that progranulin mRNA and protein were upregulated in the medial prefrontal cortex of Fmr1 knock-out mice. In Fmr1 knock-out mice, elevated progranulin caused insufficient dendritic spine pruning and late-phase long-term potentiation in the medial prefrontal cortex of Fmr1 knock-out mice. Partial progranulin knock-down restored spine morphology and reversed behavioural deficits, including impaired fear memory, hyperactivity, and motor inflexibility in Fmr1 knock-out mice. Progranulin increased levels of phosphorylated glutamate ionotropic receptor GluA1 and nuclear factor kappa B in cultured wild-type neurons. Tumour necrosis factor receptor 2 antibody perfusion blocked the effects of progranulin on GluA1 phosphorylation; this result indicates that tumour necrosis factor receptor 2 is required for progranulin-mediated GluA1 phosphorylation and late-phase long-term potentiation expression. However, high basal level of progranulin in Fmr1 knock-out mice prevented further facilitation of synaptic plasticity by exogenous progranulin. Partial downregulation of progranulin or tumour necrosis factor receptor 2/nuclear factor kappa B signalling restored synaptic plasticity and memory deficits in Fmr1 knock-out mice. These findings suggest that elevated PGRN is linked to cognitive deficits of fragile X syndrome, and the progranulin/tumour necrosis factor receptor 2 signalling pathway may be a putative therapeutic target for improving cognitive deficits in fragile X syndrome.

Keywords: TNFα; fragile X syndrome; progranulin; synaptic plasticity.

MeSH terms

  • Animals
  • Antibodies, Neutralizing / pharmacology
  • Behavior, Animal*
  • Blotting, Western
  • Cells, Cultured
  • Fluorescent Antibody Technique
  • Fragile X Mental Retardation Protein / genetics*
  • Gene Knockdown Techniques
  • Granulins
  • Intercellular Signaling Peptides and Proteins / genetics*
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Intercellular Signaling Peptides and Proteins / pharmacology
  • Learning*
  • Long-Term Potentiation / drug effects
  • Long-Term Potentiation / genetics
  • Mice
  • Mice, Knockout
  • NF-kappa B / drug effects
  • NF-kappa B / metabolism
  • Neuronal Plasticity / drug effects
  • Neuronal Plasticity / genetics
  • Neurons / drug effects
  • Neurons / metabolism
  • Phosphorylation / drug effects
  • Prefrontal Cortex / metabolism
  • Progranulins
  • RNA, Messenger / metabolism
  • Receptors, AMPA / drug effects
  • Receptors, AMPA / metabolism
  • Receptors, Tumor Necrosis Factor, Type II / immunology
  • Signal Transduction
  • Synapses / metabolism*

Substances

  • Antibodies, Neutralizing
  • Fmr1 protein, mouse
  • Granulins
  • Grn protein, mouse
  • Intercellular Signaling Peptides and Proteins
  • NF-kappa B
  • Progranulins
  • RNA, Messenger
  • Receptors, AMPA
  • Receptors, Tumor Necrosis Factor, Type II
  • Fragile X Mental Retardation Protein
  • glutamate receptor ionotropic, AMPA 1